2018 adult phone chat trials

Sponsor: Plexxikon Trial Contact Information: Divya Sakamuri; 1-713-745-3296; [email protected] Filip Janku; 713-563-1930; [email protected] Patient Involvement: ECD patients greater than 18 years of age.

Known Centers Accepting ECD patients in the trial: MD Anderson, Houston, TX Clinical Identifier: NCT02428712 Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients with Advanced Malignancies Study Objective: This study is a Phase I clinical trial to determine the recommended dose of BVD-523 for the treatment of BRAF and/or MEK positive disease. Trial Contact Information: Divya Sakamuri; 1-713-745-3296; [email protected] Filip Janku; 713-563-1930; [email protected] Patient Involvement: ECD BRAF or MEK positive patients ages 18 years or older.

There are ongoing ECD trials/studies that are currently accepting ECD patients.

Even if you or your loved one are not located near a trial/study center, you or the treating doctor are encouraged to talk to one of the researchers involved in a trial/study, prior to treatment.

The following lists more information about the open trials and studies accepting ECD patients.This will allow you to benefit from some of the leading research in the fast changing world of ECD treatments.There are currently clinical trials open for ECD treatment.Known Centers Accepting ECD patients in the trial: MD Anderson, Houston, TX Clinical Identifier: NCT02228811 Anakinra or Denosumab and Everolimus in Advanced Cancer Study Objective: The goal of this Phase I clinical research study is to determine the tolerable dose of the combination of Afinitor (everolimus) either with Kineret (anakinra) or Xgeva (denosumab) for patients with advanced cancer.Everolimus is designed to stop cells from dividing.

Leave a Reply